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Background: The purpose of this study is to analyze the outcome of patients with early glottic cancer (GC) treated
with radiotherapy (RT) with or without chemotherapy at 10 institutions in the Tokai District, Japan.
Methods: Ten institutions combined data from 279 patients with T1-T2 GC treated with RT with or without
chemotherapy between 2000 and 2005. The overall survival rate, disease-specific survival rate, and local control rate
were evaluated in 270 patients, except for incomplete cases due to issues such as discontinuation, using the
method of Kaplan-Meier and compared using the log-rank test. Results were considered statistically significant at
the level of p< 0.05.
Results: For 122 patients, the tumors were classified as T1a, while 64 patients had T1b tumors, and 84 patients had
T2 tumors. In three cases of T1 tumors, the subtype was unknown. Combined chemoradiotherapy (CRT) was
administered during each stage, and various chemotherapy drugs and regimens were used. The median follow-up
period was 55.4 months. The 5-year LC rates for T1a, Tb, and T2 tumors in all patients were 87.9%, 82.7%, and
74.1%, respectively. The difference between T1a and T2 was statistically significant (p = 0.016). The 5-year LC rates
for T1a, Tb, and T2 with CRT were 92.7%, 78.6%, and 80.7%, respectively, while the rates with radiation alone were
86.5%, 83.8%, and 64.4%, respectively. The difference between CRT and RT alone was not statistically significant in
each stage.
Conclusions: In this survey, CRT was performed for early GC at most institutions in clinical practice. Our data
showed no statistical difference in the LC rates between CRT and RT alone in each stage. However, there was a
tendency for the LCRs of the CRT group to be more favorable than those of the RT group in the T2-stage.
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Many clinical studies in the 1990s showed that concur-
rent chemoradiotherapy (CRT) improved therapeutic ef-
ficacy for local advanced head and neck cancers more
than radiotherapy (RT) alone did [1-4]. For example, in
a phase III study [5] of patients with locally advanced la-
ryngeal cancer, the rate of laryngeal preservation was
84% among patients receiving RT with concurrent cis-
platin. These studies had great impact on the treatment
of head and neck cancers in clinical practice. In* Correspondence: hnaoki@med.nagoya-u.ac.jp
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reproduction in any medium, provided the orevidence-based medicine (EBM), CRT is recommended
for laryngeal preservation in advanced cases.
On the other hand, in early glottic cancer (GC), RT
alone has been reported to be about 80-90% effective [6-
15] for local control (LC) of T1 GC and 65-80%
[6,7,10,13] effective for T2 GC. Some reports have shown
that the LC for bulky T1 is only about 70% [14,15]. The
LC rate with treatment by RT alone for bulky T1 and T2
is insufficient. According to recently published guidelines
[16,17] for the treatment of head and neck cancer, all
patients with T1-T2 laryngeal cancer should be treated,
at least initially, with the intent of larynx preservation.
The recommended strategies for early GC with the intent
of larynx preservation are radiation therapy, transoral
laser therapy, and partial laryngectomy. CRT is notal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics
T1a T1b T2
Gender (n)
Male 118 61 81
Female 4 3 3
Age (y)
Median 68 68 66
Range 43–92 44–88 46–83
Performance
status (ECOG)
0–1 113 64 77
2 3 0 1
Unknown 6 0 6
Histology
S.C.C. 122 64 84
Unknown subtype cases were taken off each table.
ECOG= Eastern Cooperative Oncology Group; S.C.C. = squamous cell
carcinoma.
Table 2 Fractionation method and radiation dose in each
stage
T1a T1b T2 Total
CF 118 51 60 229
median
dose
68 Gy 68.2 Gy 70 Gy 70 Gy
(range) ( 60–74 Gy ) ( 60–70.4 Gy ) ( 64–82 Gy ) ( 60–82 Gy)
HF 1 12 11 24
median
dose
76.8 Gy 76.8 Gy 76.8 Gy 76.8 Gy
(range) (76.8 Gy) ( 67.6-76.8 Gy ) (76.8 Gy ) (67.6-76.8 Gy)
AHF 0 0 5 5
median
dose
- - 72 Gy 72 Gy
(range) ( − ) ( − ) (60–72 Gy) (60–72 Gy)
CF +HF 2 0 4 6
median
dose
68.8 Gy - 67.1 Gy 67.1 Gy
(range) (60.8-76.8 Gy) ( − ) ( 54.4-76 Gy ) (54.4-76.8 Gy)
CF +AHF 1 1 4 6
median
dose
68 Gy 67 Gy 70 Gy 68.5 Gy
(range) ( 68 Gy ) ( 67 Gy ) ( 56.5-71 Gy ) (56.5-71 Gy)
Total 122 64 84 270
CF = conventional fractionation ; HF = fractionation ; AHF = accelerated
hyperfractionation.
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ogists in Japan believe that LC by RT alone is insufficient
in early stage GC [18-20]. Reports recently released by
several institutes in Japan [21-26] have indicated that
chemoradiation for T2GC is promising and yields LC
rates higher than those for RT alone. Therefore, chemor-
adiation for bulky T1 and T2 GC is used to improve LC
in clinical practice in Japan. The details of CRT treatment
for early GC, however, are unknown because no multi-
center survey as a comprehensive study of the patterns of
care in clinical practice has been conducted. The rates of
chemoradiotherapy for early GC according to analyses
of multiple institutions have been reported elsewhere
[19]. In this study, we analyzed the treatment outcomes of
patients with early GC treated with RT with or without
chemotherapy at 10 institutions in the Tokai District,
Japan.
Methods
The Tokai Study group for Therapeutic Radiology and
Oncology (TOSTRO) administered a questionnaire sur-
vey concerning radiotherapy for early GC in 2008. The
questionnaire included questions about the stage of can-
cer (T1a, T1b, or T2 according to the 6th UICC Inter-
national Union against the Cancer classification system,
2002), age, sex, performance status, histology, radiation
dose, fraction size, method, total radiation dose, and
combination chemotherapy among patients for whom
RT was started between January 2000 and December
2005, at about the time when CRT became popular. The
data from 10 institutions were recorded. This study was
approved by the ethics committee of each participating
hospital.
Patient characteristics
Table 1 contains a summary of the clinical characteris-
tics of the 270 patients who were included in the study.
Among all patients, 260 (96%) were male, and 10 (4%)
were female. According to the UICC system, for 122
patients, the tumors were classified as T1a, while 64
patients had T1b tumors. In only three cases of T1
tumors was the subtype unknown. The median ages of
patients were 68 years (range 43–92) in the T1a group,
68 years (range 44–88) in the T1b group, and 66 years
(range 46–83) in the T2 group. The patients included in
the survey had a histologic diagnosis of infiltrative squa-




The various fractionation methods for each stage used
during treatment of the 270 patients are summarized in
Table 2. Conventional fractionation (CF) was used for229 patients (84.8%), and hyperfractionation (HF) was
used for 24 patients (8.9%). The other patients under-
went accelerated hyperfractionation (AHF), CF plus HF,
or CF plus AHF. CF was administered at 2 Gy per frac-
tion per day. HF was delivered twice a day for a total
dose of 67.6 Gy to 76.8 Gy, with 1.2 Gy to 1.3 Gy per
fraction. In the T1a stage, CF was used for 96.7% of
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was for 71.4%. In the T2 stage, multiple fractionation
was used more often than in the T1a stage. All patients
were treated with parallel-opposed fields at 4 MV or 6
MV. Wedge filters of 15 or 30 degrees were used to
optimize the dose distribution to achieve homogeneity
of ± 5%. No prophylactic neck irradiation was performed
in any of the cases.
Chemotherapy
The rate of combined CRT at each stage and the various
chemotherapy drugs and regimens used are listed in
Table 3. Of 92 patients who had undergone combination
therapy, 81.5% had been treated with concurrent ther-
apy, 9.8% with neoadjuvant therapy, 7.6% with alterna-
tive therapy, and 1.1% with adjuvant therapy. The most
commonly used chemotherapeutic regimen was a high
dose of CDDP/5-FU followed by UFT (tegaful-uracil)
and weekly carboplatin. The other agents used in the
present study included low-dose CDDP, low-dose
CDDP/ 5-FU, docetaxel, and TS-1(tegaful/ gimeracil/
oteracil). Table 3 also shows the rates of CRT, classified
by each T stage. The difference between the combination
rate for T1a or T1b and that for T2 was statistically sig-
nificant (T1a vs. T2, p < 0.001; T1b vs.T2, p < 0.001).
Statistical analysis
The median follow-up period was 55.4 months (range,
1.7 - 96 months). LC rates were assessed from the begin-
ning of RT until evidence of recurrence or until laryn-
gectomy. The overall survival rate, disease-specific
survival rate and local control rate were evaluated in 270
patients, except for incomplete cases due to issues such
as discontinuation, using the method of Kaplan-Meier,
and compared using the log-rank test. Results were con-
sidered statistically significant at the level of p < 0.05.Table 3 Combination rates of chemotherapy and these
regimens
T1a T1b T2
Combination rate (%) 23† 22†† 60
Regimen (n)
Low dose CDDP (daily) 0 1 6
Low dose CDDP/5FU (daily) 0 1 2
High dose CDDP/5FU 9 5 17
Carboplatin (daily) 1 0 0
Carboplatin (weekly) 4 1 12
CDDP/5FU/DTX 0 0 5
DTX (Docetaxel) 1 0 2
UFT (oral antidrug) 12 5 6
TS-1 (oral antidrug) 1 1 0
† T1a vs. T2: p < 0.001; †† T1b vs. T2: p < 0.001.Results
Local response, local control, and patterns of failure
Of 279 patients, six had finished with discontinuation or
insufficient irradiation. Items from the six patients are
described as follows. Two patients were interrupted for
a simultaneous esophagus cancer. One case with 6 Gy
was stopped by aggravation of an advanced esophagus
cancer. The other completed the irradiation at 52 Gy,
and surgery was performed for esophagus cancer. The 4
remaining patients interrupted for 18 Gy, 36 Gy, 52 Gy,
and 53 Gy were changed into an operation, and each of
these is controlled by operation. Evaluation of the pri-
mary tumor effect and a local control rate were analyzed
except in these 6 patients and the 3 patients with T1 of
an unknown subtype. For the reasons presented above,
270 of 279 patients were analyzed.
At the primary site, we observed 255 complete tumor
responses (CRs) and 15 partial responses (PRs). The
overall response rate (ORR) of the 270 patients was
100%. For 270 patients, the 5-year LC rates for T1a, Tb,
and T2 were 87.9%, 82.7%, and 74.1%, respectively
(Table 4).
The difference in the LC rate for T1a and that for T2
was statistically significant (p = 0.016). Of the 270
patients, 44 (including residual cases) developed recur-
rent disease at the primary site, and 2 had lymph node
recurrences at the neck. Regarding treatment with or
without chemotherapy, the 5-year LC rates for T1a, Tb,
and T2 with CRT were 92.7%, 78.6%, and 80.7%, respect-
ively, while the rates with radiation alone were 86.5%,
83.6%, and 64.4%, respectively (Table 5 and Figures 1, 2,
and 3). The difference between CRT and RT alone was
not statistically significant in each stage. However, there
was a tendency for the LCRs of the CRT group to be
more favorable than those of the RT group in the T2
stage.
Overall survival (OS) and cause-specific survival (CSS)
rates
At the present time, 237 patients are living, and 33 have
died. eight of the 33 died of GC. Twenty-six had inter-
current diseases, including 12 with a second primary
cancer. The 5-year OS rates for T1a, Tb, and T2 wereTable 4 Local control rate and survival rate according to
the staging
T1a T1b T2 p- value
5-year local control rate 87.9% 82.7% 74.1% T1a vs. T2 p = 0.016
T1b vs. T2 p = 0.187
5-year overall survival 85.9% 90.3% 86.7% N. S.
5-year cause-specific
survival
100% 93.6% 93.5% T1a vs. T1b p = 0.013
T1a vs. T2 p = 0.006
N. S. = not significant.
Table 5 5-year local control rate with or without
chemotherapy
With Chemotherapy Radiation alone p-value
T1a 92.7% 86.5% P= 0.416
T1b 78.6% 83.8% P= 0.567
T2 80.7% 64.4% P= 0.149
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ference between the sub-stage OS rates was not statisti-
cally significant. The 5-year CSS rates for T1a, Tb, and
T2 were 100%, 93.6%, and 93.5%, respectively (Table 4).
The difference between the CSS rate for T1a or T1b and
that for the T2 stage was statistically significant (T1a vs.
T2, p = 0.013; T1b vs. T2, p = 0.006).
Complications
There were no severe acute complications with Grade 3
or above, and no patient required hospitalization due to
late complications.
Discussion
The survey showed that CRT was performed for early
GC at most institutions in clinical practice in Japan. The
rates of combination therapy for T1a, T1b, and T2 were
23%, 22%, and 60%, respectively (Table 3, T1a vs. T2,
p < 0.001; T1b vs. T2, p < 0.001). The combination rate
was higher in T2 in particular. However, CRT for early
GC is not reported in well-known textbooks of radiation
oncology [6,7]. Patients in the T2 stage with CRT under-
went a high rate of therapy, and the 5-year LC of T2 GC






















Figure 1 Local control rate for T1a tumor with or without chemotherthat for radiation alone (64.4%), but there was no statis-
tical difference between the outcomes in cases with
chemotherapy and those without chemotherapy.
Recent studies have shown an improvement in LC for
patients with T1 and T2 GC when total radiation is
delivered following a high-dose fractionation [8,27] or
hyperfractionation schedule [28-31] over a shorter over-
all treatment time. In the current study, 15% of the 270
patients were treated on hyperfractionation schedules. In
the T2 stage, the tendency toward hyperfractionation
was stronger than that in the T1a stage (Table 2). This
selection of both CRT and hyperfractionation schedules
demonstrates that most otolaryngologists and radiation
oncologists in Japan are dissatisfied with the results of
standard RT alone in early stage GC. As otolaryngolo-
gists have to perform salvage surgery for local failure,
they tend to choose combined CRT to improve the LC
rate [13]. In fact, many of the CRT regimens listed in
Table 3 are used for advanced head and neck cancers. In
short, we concluded that an improvement of CRT on LC
of advanced head and neck cancers [1-5] had significant
influence on the treatment of not only advanced cancers
but also early GC in clinical practice in Japan. Several re-
cent reports in Japan [21-26] have indicated that CRT
for T2GC is promising and yields LC rates higher than
those for RT alone. By means of these questionnaire sur-
veys, we have demonstrated that CRT for T1 and T2 GC
is used with the intent to improve LC in clinical practice
at most institutions.
In recent papers [32,33], concurrent systemic
platinum-based chemotherapy was recommended, pre-




























Figure 2 Local control rate for T1b tumor with or without chemotherapy.
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these studies, the current recommended strategy for T2
GC is CRT, and CRT for early GC will likely become
more common worldwide in the near future.
In this survey, CRT was administered for early GC in
clinical practice at most of the participating institutions;
however, whether chemotherapy is effective for patients
with very early GC, such as T1a or T1b, and whether or
not chemoradiation therapy for these very early cancers






















Figure 3 Local control rate for T2 tumor with or without chemotheraConclusions
By means of a questionnaire survey regarding RT for
early GC, we demonstrated that combined CRT was
administered for early GC in clinical practice at most of
the participating institutions. It is unknown whether
chemotherapy should be combined with definitive radio-
therapy for early GC. The results of this study showed
no statistically significant difference in LCR between the
RT group and the CRT group. However, there was a ten-
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The results of this study with several limitations suggest
that chemoradiation therapy might improve the local
control rates of patients with T2-stage cancer.
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